Healthcare Services

One of the Major Drivers of the Exocrine Pancreatic Insufficiency Market Is the Increasing Prevalence Of Chronic Diseases Boosts Growth Prospects For The Exocrine Pancreatic Insufficiency (EPI) Market

April 1, 2026April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Exocrine Pancreatic Insufficiency Market At The End Of The 2026–2030 Forecast Period?

The market size for exocrine pancreatic insufficiency has experienced substantial growth over recent years. It is projected to expand from $2.75 billion in 2025 to $2.93 billion by 2026, registering a compound annual growth rate (CAGR) of 6.5%. The historical growth can be attributed to several contributing factors, including the rising prevalence of chronic pancreatitis, heightened awareness of digestive disorders, enhanced availability of enzyme therapies, the expansion of hospital pharmacy networks, and an increased adoption of diagnostic testing.

The exocrine pancreatic insufficiency market is projected to experience robust expansion in the coming years. This market is anticipated to reach $3.88 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.3%. Key drivers for this projected growth include innovations in enzyme formulation technologies, an expanding elderly population, a heightened need for home-based care, the proliferation of online pharmacies, and enhanced reimbursement policies for digestive disorder therapies. Significant trends anticipated during this period encompass a greater uptake of pancreatic enzyme replacement therapy, an intensifying emphasis on timely and precise diagnosis, an increase in nutritional management within home settings, broader online pharmacy outreach, and better patient awareness and educational initiatives.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13107&type=smp

Which Market Drivers Are Supporting The Expansion Of The Exocrine Pancreatic Insufficiency Market?

The exocrine pancreatic insufficiency market is expected to grow as chronic diseases become more prevalent. These are long-lasting medical conditions that typically endure for three months or more. The prolonged nature of such underlying diseases can heighten the chance of developing secondary issues like exocrine pancreatic insufficiency, thereby promoting enhanced management of chronic conditions through medical interventions and therapies, which in turn can lead to longer life spans for individuals affected. As an illustration, in September 2023, the World Health Organization, a specialized agency of the United Nations based in Switzerland, documented that 41 million deaths happen each year, with 74% linked to non-communicable diseases (NCDs) or chronic diseases worldwide. Hence, the increase in chronic diseases will fuel the expansion of the exocrine pancreatic insufficiency market.

What Segment Types Make Up The Exocrine Pancreatic Insufficiency Market?

The exocrine pancreatic insufficiency market covered in this report is segmented –

1) By Treatment: Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Other Treatments

2) By Diagnosis: Imaging Tests, Computed Tomography (CT) Scan, Abdominal Ultrasound, Secretin Pancreatic Function Test, Fecal Fat Test, Fecal Elastase Test (FE-1), Other Types

3) By Symptoms: Abdominal Pain, Constipation, Diarrhea, Fatty Stools, Weight Loss, Other Symptoms

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End Users: Hospitals, Specialty Clinics, Homecare

Subsegments:

1) By Nutritional Management: Dietary Modifications, Nutritional Supplements

2) By Pancreatic Enzyme Replacement Therapy (PERT): Enteric-Coated Capsules, Non-Enteric-Coated Capsules, Powder Formulations

3) By Other Treatments: Medications, Surgical Interventions, Supportive Therapies

How Are Trends Shaping The Direction Of The Exocrine Pancreatic Insufficiency Market?

Major companies operating in the exocrine pancreatic insufficiency market are primarily focused on establishing patient advocacy groups, such as those offering comprehensive nutritional guidance, to provide extensive nutritional advice and support. These endeavors aim to heighten awareness, improve education, and enhance the management of this condition among affected individuals. Comprehensive nutritional guidance adopts a holistic approach, customizing dietary recommendations according to individual needs, health conditions, and lifestyle. It emphasizes learning, meal preparation, and sustainable practices to foster overall well-being. For example, in June 2024, Nestlé Health Science, a nutrition company based in Switzerland, launched a GLP-1 nutrition support platform. Nestlé Health Science’s GLP-1 nutrition support platform delivers personalized nutritional resources and expert guidance for people using GLP-1 medications, with a strong emphasis on muscle preservation, gut health, and general wellness. Its purpose is to empower users on their weight management journey by addressing specific dietary requirements and encouraging community support.

Who Are The Key Players Driving Competition In The Exocrine Pancreatic Insufficiency Market?

Major companies operating in the exocrine pancreatic insufficiency market are Nestlé Health Science S.A., Nordmark Arzneimittel GmbH & Co. KG, Digestive Care Inc., Enzymedica Inc., Alcresta Therapeutics Inc., Chiesi Farmaceutici S.p.A., Amryt Pharma Plc, Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Sanofi S.A., Eli Lilly and Company, Medtronic plc, First Wave BioPharma Inc., Vivus Inc., Abbott Laboratories, Danone S.A., Fresenius SE & Co. KGaA, Baxter International Inc, Siemens Healthineers AG, Thermo Fisher Scientific Inc, GE HealthCare Technologies Inc, Koninklijke Philips N.V., Fujifilm Holdings Corporation

Read the full exocrine pancreatic insufficiency market report here:

https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-global-market-report

How Is The Exocrine Pancreatic Insufficiency Market Distributed Across Key Geographic Regions?

North America was the largest region in the exocrine pancreatic insufficiency market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the exocrine pancreatic insufficiency market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Exocrine Pancreatic Insufficiency Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=13107&type=smp

Browse Through More Reports Similar to the Global Exocrine Pancreatic Insufficiency Market 2026, By The Business Research Company

Exocrine Pancreatic Insufficiency Epi Therapeutics And Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-epi-therapeutics-and-diagnostics-global-market-report

Acute Pancreatitis Global Market Report

https://www.thebusinessresearchcompany.com/report/acute-pancreatitis-global-market-report

Pancreatic Cancer Diagnostic Global Market Report

https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-diagnostic-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795